<DOC>
	<DOCNO>NCT00304759</DOCNO>
	<brief_summary>This trial design determine whether 8-week course escalate dose conformal radiation compress safely , similar efficacy 4-week course .</brief_summary>
	<brief_title>PROFIT - Prostate Fractionated Irradiation Trial</brief_title>
	<detailed_description>In trial , men intermediate risk prostate cancer randomize short course radiotherapy ( 6000cGy 20 fraction 4 weeks-hypofractionated ) treatment conventional fractionation course ( 7800cGy 39 fraction 8 weeks-standard ) . Three-dimensional conformal radiation treatment technique , include intensity modulate radiotherapy use hypofractionated standard treatment avoid normal tissue exposure radiation minimize risk acute late treatment related toxicity . The primary outcome measure biochemical ( PSA ) failure define ASTRO consensus criterion . Secondary outcome include biochemical-clinical failure ( BCF ) , mortality cancer , toxicity health-related quality life . It plan recruit 1204 patient study . If safety efficacy short course demonstrate , adoption would reduce social , emotional economic burden treatment patient family .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologic diagnosis carcinoma prostate within 6 month entry without evidence metastatic disease lymph node , bone lung ; 2 . Intermediate risk prostate cancer ( , T12a , Gleason score &lt; 6 , PSA 10.120.0 ng/ml ; T2bc Gleason &lt; 6 , PSA ≤ 20.0 ng/ml ; T12 , Gleason 7 , PSA ≤ 20.0 ng/ml ) . 1 . Histologic diagnosis carcinoma prostate six month prior study entry ; 2 . Previous therapy carcinoma prostate biopsy transurethral resection ; 3 . Patients previously 12 week hormone therapy treatment prostate cancer ; 4 . Any active malignancy ( untreated , progressive recurrent ) , except nonmelanoma skin cancer . Any inactive malignancy diagnose within 5 year entry , except nonmelanoma skin cancer ; 5 . Treatment plan meet dose constraint hypofractionation arm trial ; 6 . Previous pelvic radiotherapy ; 7 . Inflammatory bowel disease .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>localized prostate cancer</keyword>
	<keyword>intermediate risk</keyword>
	<keyword>prostate specific antigen</keyword>
	<keyword>PSA</keyword>
	<keyword>radiation fractionation</keyword>
	<keyword>shorter schedule</keyword>
	<keyword>quality life</keyword>
</DOC>